Price
No data yet.
Social Signal Score
Revenue
$56.70M+1654.81%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John Charles Jacobs
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 749
- Beta
- 2.42
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -5.78
Financials
Revenue
$56.70M+1654.8%Net Income
$-53.39MEBITDA
$-39.87MFree Cash Flow
$-74.14MEPS (diluted)
$-0.32Shares Outstanding (diluted)
164.57M+1114.3%Operating Expenses
$70.69MCash & Debt
$719.34MReturn of Capital
$8.16MRevenue by Segment (annual)
$1.37BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.12B | $440.30M | $2.72 |
| 2024 | $682.16M | $-187.50M | $-1.23 |
| 2023 | $556.38M | $-545.06M | $-5.41 |
| 2022 | $1.60B | $-657.94M | $-8.42 |
| 2021 | $197.58M | $-1.74B | $-23.44 |
| 2020 | $22.39M | $-418.26M | $-7.43 |
| 2019 | $18.66M | $-130.10M | $-5.40 |
| 2018 | $34.29M | $-184.75M | $-9.99 |
| 2017 | $31.18M | $-183.77M | $-12.56 |
| 2016 | $15.35M | $-279.97M | $-20.68 |
| 2015 | $36.25M | $-156.94M | $-11.97 |
| 2014 | $30.66M | $-82.95M | $-7.35 |
| 2013 | $20.91M | $-51.98M | $-6.13 |
| 2012 | $22.08M | $-28.51M | $-4.33 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.99
- Implied price
- $71.89
- Return from $8.98
- 51.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $35.74 — today's price is already 74.9% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | 26.8% | 32.6% | 37.6% | 41.9% | 45.7% |
| 3.0% | 33.3% | 39.4% | 44.6% | 49.1% | 53.1% |
| 8.0% | 39.8% | 46.2% | 51.6% | 56.3% | 60.6% |
| 13.0% | 46.3% | 52.9% | 58.6% | 63.6% | 68.0% |
| 18.0% | 52.7% | 59.7% | 65.6% | 70.8% | 75.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+66.67%Social Signal Score
Mentions (2)
- Newsprnewswire.com·6h ago·Neutral
…file to global markets, providing an important option for healthcare providers and patients GAITHERSBURG, Md., Aug. 28, 2026 /PRNewswire/ -- Novavax, Inc.'s (Nasdaq: NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the U.S., European Union (EU) and Japan.
View source ↗ - Newsschaeffersresearch.com·1d ago·Negative
Novavax Stock Pulls Back After Milestone Vaccine Success Drug stock Novavax Inc (NASDAQ:NVAX) is trading 2.8% lower at $9.18 this afternoon, pulling back from yesterday's surge to six-week highs.
View source ↗
Earnings
Thu, Nov 5(in 2 months)
Consensus estimate $-0.23 per share
Typical surprise +76.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.32 vs $-0.38beat
- Wed, May 6$-0.06 vs $-0.25beat
- Thu, Feb 26$0.11 vs $-0.66beat
- Thu, Nov 6$-1.25 vs $-1.08miss
- Wed, Aug 6$0.62 vs $-0.07beat
- Thu, May 8$2.93 vs $0.71beat
Estimates and results for NVAX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NVAX officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.